Systemic therapy is any cancer treatment that travels through the bloodstream to reach cells throughout the body, rather than targeting a single tumor the way surgery or radiation does. It includes chemotherapy, targeted drugs, immunotherapy, hormone-blocking agents, antibody-drug conjugates, and cell-based therapies like CAR T cells. The term “systemic” simply means body-wide, and that reach is what makes these treatments indispensable for cancers that have spread or carry a high risk of spreading. But the landscape of systemic therapy has changed dramatically over the past two decades, and the old image of a single IV drip pumping toxic chemicals is now just one small corner of the picture.
How Systemic Therapy Differs from Local Treatment
Cancer treatments generally fall into two camps. Local therapies, such as surgery and radiation, physically remove or destroy a tumor in one location. Systemic therapies circulate through the body, hunting down cancer cells wherever they may be. In a study of advanced prostate cancer, for example, “systemic therapy” referred to hormone-suppression drugs or chemotherapy given alone, while “local therapy” meant radiation or surgery combined with those same drugs. Patients who received local therapy in addition to systemic treatment had substantially better survival, illustrating a point oncologists emphasize: systemic and local approaches often work best together, not as rivals.1PubMed Central. Comparative Effectiveness of Local and Systemic Therapy for T4 Prostate Cancer
That said, systemic therapy is sometimes the only realistic option. When cancer has metastasized to multiple organs, no surgeon can chase every deposit. In blood cancers like leukemia, the disease is already widespread by definition. And even when a tumor is localized, systemic therapy before or after surgery can mop up microscopic cells that imaging cannot detect.
The Major Types of Systemic Therapy
Calling all systemic treatments “chemo” is like calling every vehicle a truck. The category is broad, and the drugs within it work in fundamentally different ways. Here is how the major classes break down.
Chemotherapy
Traditional chemotherapy targets rapidly dividing cells. Some agents, for instance, disrupt the mitotic spindle, the structure a cell builds when it divides. By jamming that machinery, the drugs trap cancer cells in a state of permanent division arrest, eventually killing them.2PubMed. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death Other chemo drugs damage DNA directly, block the enzymes cells need to copy their genetic material, or starve cells of the chemical building blocks required for growth. The common thread is that these drugs do not distinguish well between cancer cells and healthy cells that also divide quickly, which is why hair loss, mouth sores, and low blood counts are such familiar side effects.
Targeted Therapy
Targeted drugs home in on specific molecules that cancer cells depend on. A good example is thyroid cancer, where several multi-tyrosine kinase inhibitors have been approved to block the signaling proteins that fuel tumor growth. Drugs like lenvatinib, sorafenib, and cabozantinib are now standard options for different thyroid cancer subtypes, and newer agents designed to hit a single mutation, such as the RET-specific inhibitors selpercatinib and pralsetinib, offer even more precision.3PubMed. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities Because targeted drugs latch onto features that normal cells largely lack, their side-effect profiles are usually different from those of chemotherapy, though they are not free of toxicity.
Immunotherapy
The immune system has built-in brakes that prevent it from attacking the body’s own tissues. Cancer cells can hijack those brakes to hide from immune surveillance. Immune checkpoint inhibitors release those brakes. The two best-studied checkpoints are CTLA-4 and PD-1; blocking them ramps up T-cell activity and has produced durable responses in melanoma, lung cancer, and a growing list of other tumor types.4PubMed Central. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition For some patients, immunotherapy has turned what was once a terminal diagnosis into a long-term remission, which is something chemotherapy alone rarely achieves in advanced solid tumors.
Endocrine (Hormone) Therapy
Some cancers, especially breast and prostate cancer, rely on hormones to grow. Endocrine therapy cuts off that fuel supply. In breast cancer, estrogen-receptor-positive tumors can be starved with drugs that block estrogen, and emerging research shows that even the androgen receptor plays complex roles: activating it may suppress estrogen-receptor-positive disease, while blocking it may help patients whose tumors lack estrogen receptors entirely.5PubMed Central. Modulating the Activity of Androgen Receptor for Treating Breast Cancer Hormone therapies tend to be better tolerated than chemotherapy on a day-to-day basis, though they carry their own long-term effects, including bone thinning, hot flashes, and fatigue.
Antibody-Drug Conjugates
Antibody-drug conjugates, or ADCs, are sometimes described as guided missiles. They combine the targeting precision of an antibody, which locks onto a protein on the cancer cell’s surface, with a highly potent cytotoxic payload attached by a chemical linker. Once the antibody binds to its target and gets pulled inside the cell, the linker breaks and the toxic payload is released right where it does the most damage.6Molecular Cancer. Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions The payloads are often far too toxic to give on their own, but because the antibody steers them primarily to cancer cells, the collateral damage is reduced.7PubMed. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads ADCs have become a fast-growing drug class, with approvals spanning breast cancer, bladder cancer, lymphoma, and others.
CAR T-Cell Therapy
CAR T-cell therapy takes a patient’s own immune cells, genetically engineers them to recognize a specific protein on their cancer, and infuses them back in. The engineered receptor, a chimeric antigen receptor, gives the T cell both a targeting antenna and a kill switch that activates on contact with the tumor.8PubMed Central. CAR T Cell Therapy: A Versatile Living Drug This approach has produced remarkable results in certain blood cancers, with some patients achieving complete remissions after all other treatments had failed. It is still largely limited to hematologic malignancies, though trials in solid tumors are expanding.
When Systemic Therapy Is Given Relative to Surgery
Timing matters. Systemic therapy given before surgery is called neoadjuvant therapy, while the same drugs given afterward are called adjuvant therapy. The choice affects treatment goals in concrete ways.
Neoadjuvant therapy can shrink a tumor enough to make surgery less extensive. In breast cancer, that sometimes means a lumpectomy instead of a mastectomy. A large meta-analysis of individual patient data from ten randomized trials found that neoadjuvant chemotherapy was just as effective as adjuvant chemotherapy at preventing distant spread and death from breast cancer. However, tumors that had been downsized by neoadjuvant treatment showed a moderately higher rate of local recurrence, likely because breast-conserving surgery was used more often, and the original tumor boundaries were harder to define after shrinkage.9The Lancet. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials A more recent single-institution study echoed those survival findings, showing no significant difference in overall or disease-free survival between the two approaches in locally advanced breast cancer.10PubMed Central. The Impact of Neoadjuvant versus Adjuvant Chemotherapy on Survival Outcomes in Locally Advanced Breast Cancer
The calculus can differ by cancer type. In non-small cell lung cancer, a National Cancer Database analysis found that adjuvant chemotherapy provided a survival advantage over neoadjuvant chemotherapy in both stage II and stage III disease.11PubMed Central. Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database The lesson is that “before or after surgery” is not a one-size-fits-all question. It depends on the cancer’s biology, location, and the specific drugs involved.
How Systemic Therapy Is Administered
The classic image of cancer treatment involves an IV bag in an infusion center, and intravenous delivery remains common, especially for traditional chemotherapy and many immunotherapies. But there has been a meaningful shift toward oral systemic therapy, with many targeted drugs and some hormone therapies now taken as pills at home.12PubMed Central. Oral systemic therapy: Not all “win-win” Oral treatment is more convenient, but it also shifts the responsibility for dosing and schedule adherence to the patient, and side effects still need careful monitoring. Other routes include subcutaneous injection, intramuscular injection, and intrathecal delivery for cancers affecting the brain and spinal cord.
Side Effects Vary by Drug Class
Chemotherapy-induced myelosuppression, meaning a drop in the bone marrow’s production of blood cells, remains one of the most common and consequential side effects of traditional systemic therapy. Low white blood cell counts raise the risk of serious infections, anemia leads to debilitating fatigue, and low platelets increase the danger of bleeding.13PubMed Central. The impact of myelosuppression on quality of life of patients treated with chemotherapy These side effects can force dose reductions or treatment delays, which in turn may reduce the therapy’s effectiveness.
Immunotherapy has a different toxicity profile. Because checkpoint inhibitors unleash the immune system broadly, they can trigger inflammation in virtually any organ. These immune-related adverse events range from mild skin rashes to life-threatening inflammation of the heart, lungs, or nervous system. Professional guidelines recommend continuing immunotherapy with close monitoring for mild reactions, suspending treatment and considering corticosteroids for moderate ones, and permanently stopping the drug for severe toxicities except in certain hormone-related side effects that can be managed with replacement therapy.14Journal of Clinical Oncology. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update Recognizing these events early is critical, because prompt steroid treatment usually resolves them, while delayed recognition can be dangerous.
Why Cancers Stop Responding
Drug resistance is the central frustration of systemic therapy. A treatment that initially shrinks a tumor can lose its grip months or years later. Resistance develops through a remarkably varied set of mechanisms: cancer cells may pump the drug out before it can act, mutate the drug’s target so it no longer fits, activate bypass signaling pathways to keep growing despite the drug, or ramp up their DNA-repair machinery to survive the damage the drug inflicts.15PubMed Central. Understanding and targeting resistance mechanisms in cancer For molecularly targeted therapies specifically, reactivation of certain growth-signaling pathways is a recurring theme across many cancer types.16PubMed Central. Acquired resistance to molecularly targeted therapies for cancer
This is one reason oncologists rarely rely on a single systemic agent for long. Switching drug classes, adding a second agent, or rotating through planned sequences of therapy are all strategies designed to stay ahead of resistance. It is also why combination approaches have gained so much traction.
Combining Systemic Therapies with Each Other and with Radiation
Giving two systemic drugs together can sometimes produce results that neither achieves alone. One of the most active areas of research is combining chemotherapy with immunotherapy. Chemotherapy kills cancer cells in a way that spills their internal contents into the surrounding tissue, which can act like a flare for the immune system. Immunotherapy then amplifies that immune response. Studies in animal models of melanoma, prostate cancer, and colorectal cancer have shown that pairing a chemotherapy agent with an anti-PD-1 checkpoint inhibitor significantly shifted the tumor’s immune environment toward a more hostile state for cancer cells.17Nature Communications. Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer Clinical reviews have similarly highlighted the synergistic potential, noting that chemotherapy’s cell-killing effect can trigger immunogenic cell death and reshape the tumor microenvironment in ways that make immunotherapy more effective.18PubMed. Synergistic interactions and optimal sequencing of chemotherapy and immunotherapy in cancer treatment
Radiation, though technically a local therapy, is increasingly being paired with immunotherapy as well. Radiation damages tumor DNA and releases tumor-specific proteins, which can prime an immune response beyond the radiated site, a phenomenon sometimes called the abscopal effect. Clinical research suggests that combining the two modalities enhances the immune system’s ability to recognize and destroy tumor cells, potentially reducing recurrence.19PubMed Central. Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment
How Biomarker Testing Guides Treatment Choices
The shift toward precision oncology means that systemic therapy is increasingly chosen based on a tumor’s molecular profile, not just its location in the body. Multigene sequencing, sometimes called comprehensive genomic profiling, scans a tumor’s DNA for mutations, fusions, and other alterations that a specific drug can target. This technology is now recommended for most cancer types, and validated frameworks exist to help clinicians determine which genomic findings are truly actionable in daily practice.20Cell. What is systemic therapy in cancer treatment? – Section: Biomarkers to inform treatment decision-making: From oncogenes to multidimensional assessment of biology
Broad testing makes a measurable difference in treatment selection. A recent study found that patients with lung cancer who received comprehensive genomic profiling had over three times the odds of being placed on a targeted therapy compared with patients who had no testing at all. Even patients who received narrower non-comprehensive testing showed higher odds of getting a targeted drug, but the gap between comprehensive and non-comprehensive testing was itself significant.21JAMA Network Open. Biomarker Testing Approaches, Treatment Selection, and Cost of Care Among Adults With Advanced Cancer Similar patterns held for colorectal cancer in the same study. The practical takeaway: if you or someone you know has been diagnosed with an advanced cancer, asking whether genomic profiling has been done is a reasonable and often important question.
Tracking Response with Blood Tests
Traditionally, oncologists track systemic therapy’s effectiveness through imaging scans, looking for tumors to shrink or stay stable. But a newer tool is gaining clinical ground: circulating tumor DNA, or ctDNA. When cancer cells die, they shed fragments of their DNA into the bloodstream. By analyzing a simple blood draw, clinicians can detect those fragments and monitor whether a treatment is working, sometimes weeks before a scan would show the change.22PubMed Central. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology In metastatic gastrointestinal cancers, serial ctDNA monitoring has shown promise as a real-time, noninvasive readout of whether systemic therapy is hitting its mark.23PubMed Central. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
Beyond monitoring during active treatment, ctDNA is being studied for detecting minimal residual disease after surgery. If tumor DNA fragments persist in the blood after a tumor has been removed, it suggests microscopic cancer remains, and that patient may benefit from adjuvant systemic therapy. If no ctDNA is detectable, some patients might safely skip additional treatment and its side effects. This concept is still being refined in clinical trials, but it represents a meaningful step toward tailoring systemic therapy to each patient’s actual risk rather than statistical averages.
Adjusting Treatment for Older Adults
Age changes how the body handles drugs. Kidney function declines gradually, liver metabolism shifts, and the reserves that help a younger patient bounce back from a tough treatment cycle are thinner. For older patients with breast cancer, standard adjuvant systemic treatment doses often need adjustment, because the pharmacokinetics established in younger trial populations may not translate safely.24American Society of Clinical Oncology Educational Book. Systemic Therapy in Older Patients With High-Risk Disease Guidelines from the International Society of Geriatric Oncology recommend that before starting systemic therapy in elderly patients, clinicians should assess comorbidities, polypharmacy, hydration, and renal function, rather than relying solely on standard dosing tables.25PubMed. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency
This does not mean older adults should avoid systemic therapy. Many tolerate it well when doses are thoughtfully adjusted. The risk lies in two directions: overtreating and causing dangerous toxicity, or undertreating out of excessive caution and leaving effective cancer cells behind. A geriatric assessment helps oncologists find that balance.
The Financial Weight of Systemic Therapy
The cost of modern cancer drugs is hard to overstate, and financial toxicity, meaning the economic harm patients experience from treatment costs, is increasingly recognized as a real side effect of systemic therapy. In a study of over a thousand pancreatic cancer patients, roughly one in four met criteria for significant financial distress. Among those experiencing it, about half had drained their savings to pay for treatment, a third had taken on new debt, and more than a third reported skipping medications because of cost.26PubMed Central. The Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer That last figure is especially troubling, because non-adherence can directly undermine the therapy’s effectiveness.
The problem is structural, not limited to one cancer type. Cost-sharing policies have shifted more of the financial burden onto patients, and newer molecular and immune therapies tend to carry higher price tags than older chemotherapy regimens.27PubMed Central. Financial toxicity and implications for cancer care in the era of molecular and immune therapies Patients starting systemic therapy should be aware that most cancer centers now have financial navigators or social workers who can help identify assistance programs, copay support, and insurance appeals. Raising the issue early, before bills pile up, tends to produce better outcomes than waiting.
Nanoparticle Vaccines and the Frontier of Systemic Treatment
One of the more intriguing directions in systemic cancer therapy is the development of nanoparticle-based cancer vaccines. These are not vaccines in the preventive sense (like the HPV vaccine), but rather therapeutic vaccines designed to train a patient’s immune system to attack an existing tumor. Nanoparticles serve as delivery vehicles, ferrying tumor-specific proteins or even fragments of whole tumor cells to the immune cells that initiate an attack.28PubMed Central. Nanoparticle systems for cancer vaccine The same nanoparticle platforms can co-deliver adjuvants, substances that amplify the immune response, alongside personalized tumor neoantigens, which are the unique mutations that distinguish a patient’s cancer from their normal tissue.29PubMed Central. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy
Nanovaccines also open the door to combination strategies. A single nanoparticle platform can carry a chemotherapy agent or a light-activated therapeutic alongside immune-stimulating cargo, attacking the tumor through multiple pathways simultaneously. Most of this work is still in preclinical or early clinical stages, and translating nanoparticle vaccines from the lab bench to widespread clinical use involves substantial challenges in manufacturing, safety, and regulation. But the concept of a systemic treatment that is personalized down to the molecular fingerprint of an individual patient’s tumor captures where the field is heading.